Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

@inproceedings{Ferenci2021VirusNA,
  title={Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine},
  author={Tam{\'a}s Ferenci and Bal{\'a}zs Sarkadi},
  booktitle={medRxiv},
  year={2021}
}
Background: Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods: Virus neutralizing antibody titres, as a rapidly available but highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of… 

Lessons Learned from Global Administration of Sinopharm (BBIBP-CorV) Vaccine and Its Efficacy against COVID-19 in Older People

  • S. Teo
  • Medicine
    Vaccine Research
  • 2021
There is a need to take into account the heterogeneity of COVID-19 vaccine studies, such as representation of older people; and whether the results are generalizable to the target population of immunization programs.

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

  • P. RodriguezAndrea Silva Marcela Verónica Diego Sossa Candela Raffo Noelia Inés Rom Alcón Centurión Velázquez Aztorga Solazzi Bacigalu
  • Medicine
    Frontiers in Immunology
  • 2022
Evidence about the humoral response and neutralising capacity elicited by vaccination of a vulnerable elderly population is provided and could be useful for pandemic management in defining public health policies, highlighting the need to apply reinforcements after a complete vaccination schedule.

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients, and a booster dose is supported for Sinophar recipients, or those with chronic immunosuppressive diseases.

Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers

According to the results, Sputnik V and AZD-1222 vaccines were more effective than Sinopharm and Covaxin vaccines and the effectiveness of these vaccines is not related to gender.

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

In this review, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Overall, Pfizer and Sinopharm vaccines were found to be effective in limiting hospitalizations for acute cases of coronavirus among Jordanian adult's patient's cohort between February 6 and April 6, 2022, especially among patients with comorbidities.

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models

Of the three tested vaccine regimens, the middle dose of the vaccine showed the best protective immune parameters and this vaccine with heterologous prime-boost vaccination method can be a good candidate to control the viral infection and its spread by stimulating central and mucosal immunity.

Szakmai vélemény a koronavírus elleni

A magyar lakosság mind jobb védettségének elérése és az oltási program iránti közbizalom erősítése érdekében a jelenlegi, nem transzparens módon létrejött, tudományos alátámasztás nélküli, több

References

SHOWING 1-10 OF 28 REFERENCES

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Correlates of protection can be used to bridge to new populations using validated assays and extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted.

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.

COVID-19 Vaccination for People with Comorbidities

The efficacy and safety of each COVID-19 vaccine based on the presence and types of comorbidities are presented, and the guidelines recommended by the World Health Organization (WHO), as well as those implemented in the United States of America (USA) and the UK are summarized.

SARS-CoV-2 serology testing: Progress and challenges

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans, and the presence of neutralizing antibodies from prior infection was significantly associated with protection against re-infection.